Nivolumab Causing a Polymyalgia Rheumatica in a Patient With a Squamous Non-Small Cell Lung Cancer

The anti-programmed cell-death-1 antibody, nivolumab, has been recently approved for the treatment of advanced non-small cell lung cancer. Although, today, immune-related adverse effects such as dermatologic, digestive, hepatic, and endocrine toxicities are well-known with immune checkpoint inhibito...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of immunotherapy (1997) 2017-05, Vol.40 (4), p.129-131
Hauptverfasser:	Bernier, Marjorie, Guillaume, Cyril, Leon, Nathalie, Alexandre, Joachim, Hamel-Senecal, Lea, Chretien, Basile, Lecaignec, Florian, Humbert, Xavier, Fedrizzi, Sophie, Madelaine, Jeannick, Sassier, Marion
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!